Foundry Healthcare StdTurn Factor ETF
ETF Foundry Research (hypothetical) · rebalanced monthly
Every other metric on this page is the long-shortstrategy, which needs a short book. This fund is the long leg alone, so these are the figures for what it actually holds. The bottom-bucket number is that basket’s own return — not short P&L.
Hypothetical growth of $1 — long-short backtest
Gross of the placeholder expense ratio and trading costs · not investor results
Holdings
Every constituent of the long leg — sort, search or filter by sector
| Ticker | Company | Sector | Market cap | Weight |
|---|---|---|---|---|
1LLY | ELI LILLY & CO | Healthcare | $1.11T | 23.59% |
2JNJ | JOHNSON & JOHNSON | Healthcare | $609.12B | 12.94% |
3ABBV | ABBVIE INC | Healthcare | $449.63B | 9.55% |
4UNH | UNITEDHEALTH GROUP INC | Healthcare | $386.95B | 8.22% |
5MRK | MERCK & CO INC | Healthcare | $314.90B | 6.69% |
6TMO | THERMO FISHER SCIENTIFIC INC | Healthcare | $197.88B | 4.20% |
7AMGN | AMGEN INC | Healthcare | $197.69B | 4.20% |
8ABT | ABBOTT LABORATORIES | Healthcare | $175.37B | 3.73% |
9GILD | GILEAD SCIENCES INC | Healthcare | $166.72B | 3.54% |
10DHR | DANAHER CORP | Healthcare | $144.26B | 3.06% |
11CVS | CVS HEALTH CORP | Healthcare | $137.12B | 2.91% |
12VRTX | VERTEX PHARMACEUTICALS INC | Healthcare | $123.26B | 2.62% |
13SYK | STRYKER CORP | Healthcare | $122.63B | 2.60% |
14MCK | MCKESSON CORP | Healthcare | $101.14B | 2.15% |
15HCA | HCA HEALTHCARE INC | Healthcare | $82.34B | 1.75% |
16COR | CENCORA INC | Healthcare | $59.91B | 1.27% |
17ONC | BEONE MEDICINES LTD | Healthcare | $34.68B | 0.74% |
18ROIV | ROIVANT SCIENCES LTD | Healthcare | $24.82B | 0.53% |
19INCY | INCYTE CORP | Healthcare | $23.42B | 0.50% |
20DGX | QUEST DIAGNOSTICS INC | Healthcare | $23.32B | 0.50% |
21STE | STERIS PLC | Healthcare | $21.26B | 0.45% |
22MEDP | MEDPACE HOLDINGS INC | Healthcare | $15.36B | 0.33% |
23EXEL | EXELIXIS INC | Healthcare | $14.06B | 0.30% |
24SMMT | SUMMIT THERAPEUTICS INC | Healthcare | $10.72B | 0.23% |
25ENSG | ENSIGN GROUP INC | Healthcare | $10.01B | 0.21% |
26KYMR | KYMERA THERAPEUTICS INC | Healthcare | $9.52B | 0.20% |
27HALO | HALOZYME THERAPEUTICS INC | Healthcare | $9.23B | 0.20% |
28IONS | IONIS PHARMACEUTICALS INC | Healthcare | $8.99B | 0.19% |
29SYRE | SPYRE THERAPEUTICS INC | Healthcare | $8.70B | 0.18% |
30IMVT | IMMUNOVANT INC | Healthcare | $8.27B | 0.18% |
31BLLN | BILLIONTOONE INC | Healthcare | $5.99B | 0.13% |
32BLCO | BAUSCH & LOMB CORP | Healthcare | $5.80B | 0.12% |
33AMRX | AMNEAL PHARMACEUTICALS INC | Healthcare | $5.69B | 0.12% |
34RDNT | RADNET INC | Healthcare | $4.89B | 0.10% |
35ACAD | ACADIA PHARMACEUTICALS INC | Healthcare | $4.38B | 0.09% |
36EWTX | EDGEWISE THERAPEUTICS INC | Healthcare | $4.28B | 0.09% |
37CON | CONCENTRA GROUP HOLDINGS PARENT INC | Healthcare | $4.04B | 0.09% |
38ICUI | ICU MEDICAL INC | Healthcare | $3.94B | 0.08% |
39DNLI | DENALI THERAPEUTICS INC | Healthcare | $3.70B | 0.08% |
40NHC | NATIONAL HEALTHCARE CORP | Healthcare | $3.56B | 0.08% |
41GPCR | STRUCTURE THERAPEUTICS INC | Healthcare | $3.45B | 0.07% |
42PRVA | PRIVIA HEALTH GROUP INC | Healthcare | $3.39B | 0.07% |
43IDYA | IDEAYA BIOSCIENCES INC | Healthcare | $3.16B | 0.07% |
44IRON | DISC MEDICINE INC | Healthcare | $2.91B | 0.06% |
45SUPN | SUPERNUS PHARMACEUTICALS INC | Healthcare | $2.79B | 0.06% |
46GRDN | GUARDIAN PHARMACY SERVICES INC | Healthcare | $2.57B | 0.05% |
47PBH | PRESTIGE CONSUMER HEALTHCARE INC | Healthcare | $2.36B | 0.05% |
48MD | PEDIATRIX MEDICAL GROUP INC | Healthcare | $2.15B | 0.05% |
49AVAH | AVEANNA HEALTHCARE HOLDINGS INC | Healthcare | $2.11B | 0.04% |
50SGRY | SURGERY PARTNERS INC | Healthcare | $2.09B | 0.04% |
51PLSE | PULSE BIOSCIENCES INC | Healthcare | $1.98B | 0.04% |
52MRVI | MARAVAI LIFESCIENCES HOLDINGS INC | Healthcare | $1.87B | 0.04% |
53ZYME | ZYMEWORKS INC | Healthcare | $1.77B | 0.04% |
54INNV | INNOVAGE HOLDING CORP | Healthcare | $1.56B | 0.03% |
55SEPN | SEPTERNA INC | Healthcare | $1.51B | 0.03% |
56AHCO | ADAPTHEALTH CORP | Healthcare | $1.49B | 0.03% |
57PNTG | PENNANT GROUP INC | Healthcare | $1.46B | 0.03% |
58ARDT | ARDENT HEALTH INC | Healthcare | $1.46B | 0.03% |
59KMTS | KESTRA MEDICAL TECHNOLOGIES LTD | Healthcare | $1.43B | 0.03% |
60PAHC | PHIBRO ANIMAL HEALTH CORP | Healthcare | $1.35B | 0.03% |
61USPH | U S PHYSICAL THERAPY INC | Healthcare | $1.12B | 0.02% |
62LMRI | LUMEXA IMAGING HOLDINGS INC | Healthcare | $1.07B | 0.02% |
63BVS | BIOVENTUS INC | Healthcare | $1.01B | 0.02% |
64LBRX | LB PHARMACEUTICALS INC | Healthcare | $901M | 0.02% |
65HSTM | HEALTHSTREAM INC | Healthcare | $832M | 0.02% |
66AURA | AURA BIOSCIENCES INC | Healthcare | $723M | 0.02% |
67BBOT | BRIDGEBIO ONCOLOGY THERAPEUTICS INC | Healthcare | $686M | 0.01% |
68SGP | SPYGLASS PHARMA INC | Healthcare | $661M | 0.01% |
69GYRE | GYRE THERAPEUTICS INC | Healthcare | $587M | 0.01% |
70ANGO | ANGIODYNAMICS INC | Healthcare | $558M | 0.01% |
71NPCE | NEUROPACE INC | Healthcare | $548M | 0.01% |
72EIKN | EIKON THERAPEUTICS INC | Healthcare | $529M | 0.01% |
73KIDS | ORTHOPEDIATRICS CORP | Healthcare | $494M | 0.01% |
74NRC | NRC HEALTH | Healthcare | $491M | 0.01% |
75OFIX | ORTHOFIX MEDICAL INC | Healthcare | $468M | 0.01% |
76VMD | VIEMED HEALTHCARE INC | Healthcare | $466M | 0.01% |
77SI | SHOULDER INNOVATIONS INC | Healthcare | $448M | 0.01% |
78BNTC | BENITEC BIOPHARMA INC | Healthcare | $439M | 0.01% |
79DMAC | DIAMEDICA THERAPEUTICS INC | Healthcare | $393M | 0.01% |
80FENC | FENNEC PHARMACEUTICALS INC | Healthcare | $365M | 0.01% |
81CV | CAPSOVISION INC | Healthcare | $335M | 0.01% |
82CARL | CARLSMED INC | Healthcare | $317M | 0.01% |
83FHTX | FOGHORN THERAPEUTICS INC | Healthcare | $305M | 0.01% |
84MASS | 908 DEVICES INC | Healthcare | $278M | 0.01% |
85SGHT | SIGHT SCIENCES INC | Healthcare | $274M | 0.01% |
86TTRX | TURN THERAPEUTICS INC | Healthcare | $272M | 0.01% |
87TRDA | ENTRADA THERAPEUTICS INC | Healthcare | $268M | 0.01% |
88SMTI | SANARA MEDTECH INC | Healthcare | $229M | 0.00% |
89UTMD | UTAH MEDICAL PRODUCTS INC | Healthcare | $222M | 0.00% |
90FOCL | FOCAL INC | Healthcare | $204M | 0.00% |
91ACOG | ALPHA COGNITION INC | Healthcare | $185M | 0.00% |
92INFU | INFUSYSTEM HOLDINGS INC | Healthcare | $180M | 0.00% |
93OWLT | OWLET INC | Healthcare | $162M | 0.00% |
94RCEL | AVITA MEDICAL INC | Healthcare | $157M | 0.00% |
95JYNT | JOINT CORP | Healthcare | $127M | 0.00% |
96ICCC | IMMUCELL CORP | Healthcare | $101M | 0.00% |
97CSBR | CHAMPIONS ONCOLOGY INC | Healthcare | $85M | 0.00% |
98EXOZ | EXOZYMES INC | Healthcare | $51M | 0.00% |
Full long-leg book as of July 2026 · cap-weighted · total market cap $4.71T. Hypothetical model holdings — not a registered fund’s portfolio.
Sector Breakdown
Portfolio Style
Size × value map of the long-leg book
Share of long-leg capital by market cap × book-to-market, using terciles of the 499-name universe at July 2026. Rows: Large ≥ $3.6B, Small < $964M. Columns: Value ≥ 0.67, Growth < 0.37 B/M. The dot marks the capital-weighted centroid of the book — 99% toward Large, 67% toward Growth. Hypothetical holdings — descriptive, not realized P&L.
Capital-weighted centroid of the long leg, December 1998 → July 2026; the right-hand end is the same value as the box’s dot. 98 names now. Hypothetical holdings — descriptive, not P&L.
Constraint checks
How this book measures against the concentration and liquidity rules — as implemented here
These are UNCONSTRAINED factor sleeves: the construction pipeline sorts on a signal and cap-weights the top bucket, applying no issuer cap, no industry cap and no liquidity screen beyond the universe filter. A failing test therefore reports a constraint that was never applied during construction — it is not a defect in the strategy and not an error in the data. The same signal can be solved subject to these constraints.
7 independent checks plus 1 arithmetically implied by another check (RIC / IRC 851(b)(3)(A) 50% bucket), which is reported separately so the tally cannot overstate scrutiny.
1 of 7 checks could not be tested. Those are neither passes nor failures — they are gaps in what the data can answer, and they are excluded from the passed count above rather than folded into it.
With respect to 75% of total assets, no more than 5% may be invested in the securities of any one issuer.
Required>= 75.0%Actual64.0%Margin-11.0%
Engineering approximation of the cited rules for a DRAFT / HYPOTHETICAL model portfolio that is not a registered fund. This reports whether the portfolio passes the stated test AS IMPLEMENTED HERE; it is not a compliance opinion and is not a statement that any fund is compliant. Real filings need securities counsel.
No verdict sits within 1.0pp of its limit.
Data version — panel=20260719T025334 rows=2239262 asof=202607 issuers=20260719T014536 rates=20260804T224700
Measured on the 2026-07 formation date across 98 holdings (cap-weighted). A different formation date can produce different verdicts.
Derivatives risk (Rule 18f-4)
Whether this long-only book is subject to the VaR tests at all
This assessment describes the long-only book this fund holds — the top bucket only.
This fund QUALIFIES for the limited-derivatives-user exception, so it is excepted from the VaR tests; the ratio below is informational, not the operative limit.
Rule 18f-4(c)(4): a fund whose derivatives exposure (gross notional, including the value of assets sold short) is <= 10% of net assets is excepted from the VaR tests and the full derivatives risk management program.
No confidence interval: this follows from portfolio construction, not from an estimate.
Rule 18f-4(c)(2)(i): fund VaR at 99% over 20 trading days must not exceed 200% of the designated reference portfolio's VaR on the same basis.
Informational — does not governThis fund is excepted from the VaR tests, so the ratio below is context rather than the operative limit. It is shown because it is still a description of the book’s risk, not because it decides anything.
historical method · 331 monthly observations · about 3.3 in the 99% tail · paired percentile bootstrap over months
The estimators differ materially in value but agree on the verdict. Historical and Gaussian fund VaR differ by 18%; both still land on the same side of the 2x limit.
Engineering approximation of SEC Rule 18f-4 for research display. Not a compliance opinion and not a determination that any fund is compliant. Hypothetical model portfolio, not a registered fund.
The research long-short construction behind this factor does not qualify for this exception — a dollar-neutral book counts its full short notional, which is 100% of net assets against a 10% threshold. This product sidesteps that by holding the long leg alone, which is also why the long-leg Sharpe is reported separately throughout the site.
See the long-short verdict on the factor page →Since publication
Did the edge survive the paper coming out?
Split at January of the year after the factor was published. The post-publication stretch IS genuinely out-of-sample relative to the original study -- the predictor was public by then -- so it speaks to whether the effect survived being known. Nothing is fitted here, so this is performance SINCE PUBLICATION, not validation of a model. Note the 'pre' side is our data before publication (our panel starts ~1999), NOT the study's original in-sample period, which usually ran decades earlier; a decay figure compares before-vs-after within our sample and is not a comparison against the published result.
Consistency across eras
Is this record broadly durable, or one regime?
3-year rolling windows, stepping 1 year (26 windows). Dispersion is the spread of window Sharpes — higher means the record depends more on which era you look at.
Rules-based factors fit no parameters, so these windows are not out-of-sample tests and do not validate a fitted model. They show whether the factor's record is consistent across eras or driven by one regime.
Returns
Long leg is what this fund holds — long-short is shown for reference
| Period | Long leg | Long-short |
|---|---|---|
| 1 yearcum. | 25.8% | -21.0% |
| 3 yearsp.a. | 12.7% | -1.7% |
| 5 yearsp.a. | 8.6% | 9.2% |
| 10 yearsp.a. | 11.8% | -2.0% |
| Since inceptionp.a. | 7.8% | -4.5% |
| Year | Long leg | Long-short |
|---|---|---|
| 20267 mo | 3.5% | -12.3% |
| 2025 | 25.4% | 5.2% |
| 2024 | 7.1% | 12.7% |
| 2023 | 4.9% | -16.0% |
| 2022 | -3.6% | 32.7% |
| 2021 | 26.0% | 21.2% |
| 2020 | 16.5% | -27.3% |
| 2019 | 20.5% | -12.7% |
| 2018 | 10.0% | 9.0% |
| 2017 | 19.6% | -10.1% |
| 2016 | 4.1% | 31.7% |
| 2015 | 3.5% | -5.5% |
| 2014 | 23.2% | -11.7% |
| 2013 | 42.1% | -11.4% |
| 2012 | 13.7% | -10.7% |
| 2011 | 13.2% | 5.3% |
| 2010 | 2.5% | -12.1% |
| 2009 | 12.1% | -27.3% |
| 2008 | -20.4% | 9.4% |
| 2007 | 6.8% | -0.8% |
| 2006 | 7.3% | 7.7% |
| 2005 | 5.3% | 5.6% |
| 2004 | -2.9% | -14.1% |
| 2003 | 12.2% | -18.9% |
| 2002 | -19.4% | 32.0% |
| 2001 | -12.4% | -6.7% |
| 2000 | 37.0% | -35.4% |
| 1999 | -13.4% | -19.1% |
Long leg = the top bucket this fund holds; long-short additionally shorts the bottom bucket and is not achievable in a long-only vehicle. Trailing figures run through July 2026: 1 year is a plain cumulative 12-month return (cum.), 3 years and longer are annualised (p.a.). Years marked with a month count are partial. These match the fact sheet’s tables by construction. Hypothetical backtest, gross of the placeholder expense ratio and trading costs — not investor results.
Fund Facts
Methodology
The Foundry Healthcare StdTurn Factor ETF tracks a rules-based model that ranks Healthcare common stocks each month by a StdTurn signal and holds the top quintile with the lowest values. Signals are computed from point-in-time Sharadar fundamentals and total-return prices. The portfolio reconstitutes monthly and is cap-weighted within the long leg.
This is a hypothetical model portfolio for research display only — not a registered fund, not an offer, and not investment advice.
Documents (draft — hypothetical)
Auto-generated from the model’s metrics and current holdings. Every document is labeled DRAFT / hypothetical.
Objective, fees, strategy, and key risks.
Full strategy, model methodology, and risks.
Policies, construction, and governance.
One-page snapshot with top holdings.
Full current constituent list.
DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.